Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes

Cytokine

Volumn 12, Issue 6, 2000, Pages 774-779

  Paysant, Jerome ^c   Blanqué, Roland ^a   Vasse, Marc ^c   Soria, Claudine ^c   Soria, Jeannette ^b   Gardner, Colin R ^a  

^a SANOFI   (France)

^b HÔTEL DIEU   (France)

^c NONE

Author keywords

Dexamethasone; Fibrinogen; HepG2 hepatocytes; Soluble IL 6 receptor

Indexed keywords

DEXAMETHASONE; FIBRINOGEN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; COMPLEX FORMATION; CONTROLLED STUDY; FIBRINOGEN SYNTHESIS; INTERNALIZATION; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0033921266     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0649     Document Type: Article

References (15)

1. Heinrich PC, Graeve L, Rose-John S, Schneider-Mergener J, Dittrich E, Erren A, Gerhartz C, Hemmann U, Lutticken C, Wegenka U, Weiergraber O, Horn D. Membrane bound and soluble IL-6 receptor: studies on structure, regulation of expression and signal transduction. Ann NY Acad Sci. 762:1995;222-236.
2. Cichy J, Rose-John S, Potempa J, Pryjma J, Travis J. Oncostatin M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells. J Immunol. 159:1997;5648-5653.
3. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine. 4:1992;96-100.
4. Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki MN, Matsumoto A, Yamamoto M, Yamamoto N. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol. 24:1994;1945-1948.
5. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Anderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarns K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ, Black RA. Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature. 370:1994;218-220.
6. Heaney ML, Golde DW. Soluble cytokine receptors. Blood. 87:1996;847-857.
7. Kyrtsonis M-C, Dedoussis C, Zervas C, Perifanis V, Baxevanis C, Stamatelou M, Maniatis A. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol. 93:1996;398-400.
8. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA. 84:1987;7251-7255.
9. Paysant J, Vasse M, Blanqué R, Soria C, Soria J, Gardner CR. Potentiation of IL6 responses by soluble IL6 receptor depends on the ligand/membrane receptor Ratio. Eur Cytokine Netw. 7:1995;613.
10. Geisterfer M, Richards CD, Gauldie J. Cytokines oncostatin M and interleukin-1 regulate the expression of the IL-6 receptor (gp80, gp130). Cytokine. 7:1995;503-509.
11. Snyers L, De Wit L, Content J. Glucocorticoid up-regulation of high-affinity interleukin 6 receptors on human epithelial cells. Proc Natl Acad Sci USA. 87:1990;2838-2842.
12. Gabay C, Sillaci P, Genin B, Meutron G, Le Coultre C, Guerne PA. Soluble IL-6 receptor strongly increases the production of acute phase proteins by hepatoma cells but exerts minimal changes on human primary hepatocytes. Eur J Immunol. 25:1995;2378-2383.
13. Schooltink H, Schmitz-Van de Leur H, Heinrich PC, Rose-John S. Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS. 297:1992;263-265.
14. Zohlnofer D, Graeve L, Rose-John S, Schooltink H, Dittrich E, Heinrich PC. The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett. 306:1992;219-222.
15. Vasse M, Paysant J, Soria J, Collet JP, Vannier JP, Soria C. Regulation of fibrinogen synthesis by cytokines, consequences on the vascular risk. Haemostasis. 26:1996;331-339.